Stockreport

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focu [Read more]